Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

SciSparc Ltd. SPRC

Healthcare  —  Biotechnology
5.21 (0.18) (3.34%) as of 25 Sep
Market cap
$3.1M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

SciSparc Ltd. (SPRC) Business Profile

Updated before January 2025

Company Overview

SciSparc Ltd. (NASDAQ: SPRC) is a clinical-stage pharmaceutical company focused on developing innovative therapies to address central nervous system (CNS) disorders. The company was founded in 2004 and is headquartered in Tel Aviv, Israel. SciSparc leverages its proprietary cannabinoid-based technologies to create novel treatments for a range of conditions, including Tourette syndrome, Alzheimer’s disease, and pain management. The company is led by a team of experienced professionals, including its CEO, Oz Adler, who brings extensive expertise in biotechnology and pharmaceutical development. The leadership team is committed to advancing the company’s mission of improving the quality of life for patients through cutting-edge science and innovation.

Core Business Segments

Cannabinoid-Based Therapies

SciSparc specializes in the development of cannabinoid-based therapies targeting CNS disorders. Its flagship products include:

  • SCI-110: A proprietary combination of cannabinoids and other compounds designed to treat Tourette syndrome and obstructive sleep apnea.
  • SCI-210: A formulation aimed at addressing autism spectrum disorder and epilepsy.
  • SCI-160: A pain management therapy currently in preclinical development.

Pharmaceutical Development

The company also focuses on advancing its pipeline of pharmaceutical products through rigorous clinical trials. SciSparc collaborates with leading research institutions and leverages its proprietary technology to enhance the efficacy and safety of its treatments.

Partnerships and Licensing

SciSparc actively seeks partnerships and licensing opportunities to expand its reach and accelerate the development of its therapies. The company collaborates with academic institutions, research organizations, and other pharmaceutical companies to bring its products to market.

Business Model

SciSparc operates on a business model that integrates research, development, and commercialization. The company invests heavily in R&D to create innovative therapies and conducts clinical trials to validate their efficacy and safety. Revenue generation is primarily achieved through licensing agreements, partnerships, and eventual product sales. SciSparc’s approach emphasizes collaboration with external stakeholders to maximize the impact of its therapies and ensure their accessibility to patients worldwide.

Strategic Direction

SciSparc is focused on expanding its pipeline of cannabinoid-based therapies and exploring new indications for its existing products. The company aims to:

  • Advance its clinical trials for SCI-110, SCI-210, and SCI-160.
  • Explore additional CNS disorders that could benefit from its proprietary technologies.
  • Strengthen its partnerships with research institutions and pharmaceutical companies.
  • Incorporate sustainability practices into its operations, including ethical sourcing of raw materials and minimizing its environmental footprint.
  • Expand its presence in global markets, particularly in North America and Europe.

Competitive Landscape

SciSparc operates in a competitive landscape that includes both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • GW Pharmaceuticals: A leader in cannabinoid-based therapies, known for its product Epidiolex.
  • Zynerba Pharmaceuticals: Focused on transdermal cannabinoid therapies.
  • Jazz Pharmaceuticals: Specializes in CNS disorders and has a strong portfolio of related products.
  • Arena Pharmaceuticals: Develops therapies for pain management and other conditions.

Despite the competition, SciSparc differentiates itself through its proprietary technologies and focus on underserved CNS disorders.

Risk Factors

SciSparc faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The development and approval of cannabinoid-based therapies are subject to stringent regulatory requirements.
  • Market Dependence: The company’s success is heavily reliant on the commercial viability of its products.
  • Supply Chain Disruptions: Sourcing raw materials and manufacturing products could be affected by global supply chain issues.
  • Competition: The presence of established players in the cannabinoid-based therapy market poses a significant challenge.
  • Financial Risks: As a clinical-stage company, SciSparc depends on external funding to support its operations and may face difficulties in securing additional capital.

Recent Developments

In recent months, SciSparc has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Trials: The company initiated Phase IIb trials for SCI-110 to evaluate its efficacy in treating Tourette syndrome.
  • Partnerships: SciSparc entered into a collaboration with a leading research institution to explore new applications for its technologies.
  • Corporate Strategy: The company announced plans to expand its operations in North America and strengthen its presence in the European market.
  • Global Developments: The COVID-19 pandemic highlighted the importance of mental health and CNS therapies, creating new opportunities for SciSparc’s products.

Investment Considerations

Strengths

  • Innovative Pipeline: SciSparc’s focus on cannabinoid-based therapies for CNS disorders positions it as a leader in a niche market.
  • Experienced Leadership: The company’s management team has a proven track record in pharmaceutical development.
  • Strategic Partnerships: Collaborations with research institutions and other companies enhance its R&D capabilities.
  • Market Potential: The growing demand for CNS therapies presents significant growth opportunities.

Risks

  • Regulatory Hurdles: The approval process for new therapies is lengthy and uncertain.
  • Financial Dependence: The company relies on external funding to sustain its operations.
  • Competitive Pressure: Established players in the market could limit SciSparc’s growth potential.

Conclusion

SciSparc Ltd. is a pioneering company in the field of cannabinoid-based therapies for CNS disorders. With a robust pipeline, experienced leadership, and strategic partnerships, the company is well-positioned to capitalize on the growing demand for innovative treatments. However, it faces challenges such as regulatory hurdles and financial dependence. Overall, SciSparc’s commitment to innovation and patient care makes it a promising player in the pharmaceutical industry, with significant growth potential in the years ahead.